Free Trial
NASDAQ:NEUP

Neuphoria Therapeutics Inc. - Common Stock (NEUP) Stock Price, News & Analysis

Neuphoria Therapeutics Inc. - Common Stock logo
$5.05 +0.05 (+1.00%)
As of 05/2/2025 03:24 PM Eastern

About Neuphoria Therapeutics Inc. - Common Stock Stock (NASDAQ:NEUP)

Key Stats

Today's Range
$4.93
$5.25
50-Day Range
$4.64
$5.80
52-Week Range
$2.12
$15.24
Volume
9,423 shs
Average Volume
416,957 shs
Market Capitalization
$8.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc. - Common Stock Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

NEUP MarketRank™: 

Neuphoria Therapeutics Inc. - Common Stock scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Neuphoria Therapeutics Inc. - Common Stock are expected to decrease in the coming year, from ($1.56) to ($1.85) per share.

  • Price to Book Value per Share Ratio

    Neuphoria Therapeutics Inc. - Common Stock has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for NEUP.
  • Dividend Yield

    Neuphoria Therapeutics Inc. - Common Stock does not currently pay a dividend.

  • Dividend Growth

    Neuphoria Therapeutics Inc. - Common Stock does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NEUP.
  • News Sentiment

    Neuphoria Therapeutics Inc. - Common Stock has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Neuphoria Therapeutics Inc. - Common Stock insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.69% of the stock of Neuphoria Therapeutics Inc. - Common Stock is held by insiders.

  • Percentage Held by Institutions

    Only 15.90% of the stock of Neuphoria Therapeutics Inc. - Common Stock is held by institutions.

  • Read more about Neuphoria Therapeutics Inc. - Common Stock's insider trading history.
Receive NEUP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuphoria Therapeutics Inc. - Common Stock and its competitors with MarketBeat's FREE daily newsletter.

NEUP Stock News Headlines

Neuphoria Therapeutics provides review of 2024, highlights 2025 plans
U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.
See More Headlines

NEUP Stock Analysis - Frequently Asked Questions

Neuphoria Therapeutics Inc. - Common Stock's stock was trading at $3.20 at the start of the year. Since then, NEUP stock has increased by 57.8% and is now trading at $5.05.
View the best growth stocks for 2025 here
.

Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) issued its earnings results on Friday, February, 14th. The company reported ($1.23) earnings per share for the quarter, beating analysts' consensus estimates of ($2.01) by $0.78. The business earned $660 billion during the quarter.

Top institutional investors of Neuphoria Therapeutics Inc. - Common Stock include Cyndeo Wealth Partners LLC (0.57%).

Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
2/14/2025
Today
5/02/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NEUP
Previous Symbol
NASDAQ:NEUP
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+315.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$662,715.00
Price / Cash Flow
N/A
Book Value
$7.82 per share
Price / Book
0.65

Miscellaneous

Free Float
1,745,000
Market Cap
$8.87 million
Optionable
N/A
Beta
0.25
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:NEUP) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners